These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21427648)

  • 21. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy.
    Franz M; Berndt A; Altendorf-Hofmann A; Fiedler N; Richter P; Schumm J; Fritzenwanger M; Figulla HR; Brehm BR
    Eur J Heart Fail; 2009 Nov; 11(11):1057-62. PubMed ID: 19815660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum matrix metalloproteinases and tympanosclerosis.
    Aslan H; Başoğlu MS; Sentürk B; Ozbay C; Katilmiş H; Oztürkcan S
    J Laryngol Otol; 2011 Feb; 125(2):142-6. PubMed ID: 20955636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
    Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
    Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms.
    Schmoker JD; McPartland KJ; Fellinger EK; Boyum J; Trombley L; Ittleman FP; Terrien C; Stanley A; Howard A
    J Thorac Cardiovasc Surg; 2007 Jan; 133(1):155-61. PubMed ID: 17198804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with incisional hernia.
    Henriksen NA; Sørensen LT; Jorgensen LN; Agren MS
    Wound Repair Regen; 2013; 21(5):661-6. PubMed ID: 23927724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of impact and non-impact exercise on circulating markers of collagen remodelling in humans.
    Mackey AL; Donnelly AE; Swanton A; Murray F; Turpeenniemi-Hujanen T
    J Sports Sci; 2006 Aug; 24(8):843-8. PubMed ID: 16815778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism.
    Mühl D; Ghosh S; Uzuelli JA; Lantos J; Tanus-Santos JE
    Thromb Res; 2010 Jun; 125(6):549-53. PubMed ID: 20307903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M; Puistola U; Turpeenniemi-Hujanen T
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
    Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K
    Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features.
    Bruno CM; Valenti M; Bertino G; Ardiri A; Consolo M; Mazzarino CM; Amoroso A; Neri S
    Panminerva Med; 2009 Dec; 51(4):191-6. PubMed ID: 20195229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced levels of MMP-2 and TIMP-1 in dyssegmental dysplasia.
    Uchide K; Ueno H; Takizawa N; Okada Y
    J Bone Miner Res; 2003 Feb; 18(2):381-2. PubMed ID: 12568417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
    Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
    Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.